300 related articles for article (PubMed ID: 33846495)
1. Detecting early onset of anthracyclines-induced cardiotoxicity using a novel panel of biomarkers in West-Virginian population with breast cancer.
Lakhani HV; Pillai SS; Zehra M; Dao B; Tirona MT; Thompson E; Sodhi K
Sci Rep; 2021 Apr; 11(1):7954. PubMed ID: 33846495
[TBL] [Abstract][Full Text] [Related]
2. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy.
Tzolos E; Adamson PD; Hall PS; Macpherson IR; Oikonomidou O; MacLean M; Lewis SC; McVicars H; Newby DE; Mills NL; Lang NN; Henriksen PA
Clin Oncol (R Coll Radiol); 2020 May; 32(5):292-297. PubMed ID: 31813662
[TBL] [Abstract][Full Text] [Related]
3. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients.
Shafi A; Siddiqui N; Imtiaz S; Din Sajid MU
J Ayub Med Coll Abbottabad; 2017; 29(2):266-269. PubMed ID: 28718245
[TBL] [Abstract][Full Text] [Related]
4. [Troponin I and B-type Natriuretic Peptide (BNP) as biomarkers for the prediction of cardiotoxicity in patients with breast cancer treated with adjuvant anthracyclines and trastuzumab].
Pistillucci G; Ciorra AA; Sciacca V; Raponi M; Rossi R; Veltri E
Clin Ter; 2015; 166(1):e67-71. PubMed ID: 25756270
[TBL] [Abstract][Full Text] [Related]
5. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.
Leger KJ; Leonard D; Nielson D; de Lemos JA; Mammen PP; Winick NJ
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28377429
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
[TBL] [Abstract][Full Text] [Related]
7. The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study.
Lenihan DJ; Stevens PL; Massey M; Plana JC; Araujo DM; Fanale MA; Fayad LE; Fisch MJ; Yeh ET
J Card Fail; 2016 Jun; 22(6):433-8. PubMed ID: 27079675
[TBL] [Abstract][Full Text] [Related]
8. Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: A narrative review.
Simões R; Silva LM; Cruz ALVM; Fraga VG; de Paula Sabino A; Gomes KB
Biomed Pharmacother; 2018 Nov; 107():989-996. PubMed ID: 30257411
[TBL] [Abstract][Full Text] [Related]
9. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
10. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study.
Gulati G; Heck SL; Røsjø H; Ree AH; Hoffmann P; Hagve TA; Norseth J; Gravdehaug B; Steine K; Geisler J; Omland T
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29118031
[TBL] [Abstract][Full Text] [Related]
11. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients.
Kitayama H; Kondo T; Sugiyama J; Kurimoto K; Nishino Y; Kawada M; Hirayama M; Tsuji Y
Breast Cancer; 2017 Nov; 24(6):774-782. PubMed ID: 28434150
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity.
Mahjoob MP; Sheikholeslami SA; Dadras M; Mansouri H; Haghi M; Naderian M; Sadeghi L; Tabary M; Khaheshi I
Cardiovasc Hematol Disord Drug Targets; 2020; 20(1):74-83. PubMed ID: 31513000
[TBL] [Abstract][Full Text] [Related]
13. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
14. The relationship between plasma hyaluronan levels and anthracycline-related cardiotoxicity in breast cancer patients.
Inanc MT; Karadavut S; Aytekin M; Duran AO; Derya M; Akpek M; Sahin O; Kalay N; Karaca H; Ozkan M; Inanc M
Int J Cardiol; 2016 Sep; 218():246-251. PubMed ID: 27236123
[TBL] [Abstract][Full Text] [Related]
15. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
16. Are Biomarkers Predictive of Anthracycline-Induced Cardiac Dysfunction?
Malik A; Jeyaraj PA; Calton R; Uppal B; Negi P; Shankar A; Patil J; Mahajan MK
Asian Pac J Cancer Prev; 2016; 17(4):2301-5. PubMed ID: 27221934
[TBL] [Abstract][Full Text] [Related]
17. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
Sawaya H; Sebag IA; Plana JC; Januzzi JL; Ky B; Tan TC; Cohen V; Banchs J; Carver JR; Wiegers SE; Martin RP; Picard MH; Gerszten RE; Halpern EF; Passeri J; Kuter I; Scherrer-Crosbie M
Circ Cardiovasc Imaging; 2012 Sep; 5(5):596-603. PubMed ID: 22744937
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatic analysis of peripheral blood miRNA of breast cancer patients in relation with anthracycline cardiotoxicity.
Yadi W; Shurui C; Tong Z; Suxian C; Qing T; Dongning H
BMC Cardiovasc Disord; 2020 Feb; 20(1):43. PubMed ID: 32013934
[TBL] [Abstract][Full Text] [Related]
19. Early and late onset cardiotoxicity following anthracycline-based chemotherapy in breast cancer patients: Incidence and predictors.
Serrano JM; Mata R; González I; Del Castillo S; Muñiz J; Morales LJ; Espinosa MJ; Moreno F; Jiménez R; Cristobal C; Graupner C; Talavera P; Landaluce CG; Curcio A; Alonso J; Guerra JA; Alonso JJ
Int J Cardiol; 2023 Jul; 382():52-59. PubMed ID: 37080467
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxic effects and myocardial injury: the search for a more precise definition of drug cardiotoxicity.
Cardinale DM; Zaninotto M; Cipolla CM; Passino C; Plebani M; Clerico A
Clin Chem Lab Med; 2020 Aug; 59(1):51-57. PubMed ID: 32845860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
